Nathaniel L. Wilganowski
Lexicon Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nathaniel L. Wilganowski.
Frontiers in Endocrinology | 2015
David R. Powell; Nathaniel L. Wilganowski; Deon Doree; Katerina V. Savelieva; Thomas H. Lanthorn; Robert Read; Peter Vogel; Gwenn Hansen; Robert Brommage; Zhi-Ming Ding; Urvi Desai; Brian Zambrowicz
After creating >4,650 knockouts (KOs) of independent mouse genes, we screened them by high-throughput phenotyping and found that cannabinoid receptor 1 (Cnr1) KO mice had the same lean phenotype published by others. We asked if our KOs of DAG lipase α or β (Dagla or Daglb), which catalyze biosynthesis of the endocannabinoid (EC) 2-arachidonoylglycerol (2-AG), or Napepld, which catalyzes biosynthesis of the EC anandamide, shared the lean phenotype of Cnr1 KO mice. We found that Dagla KO mice, but not Daglb or Napepld KO mice, were among the leanest of 3651 chow-fed KO lines screened. In confirmatory studies, chow- or high fat diet-fed Dagla and Cnr1 KO mice were leaner than wild-type (WT) littermates; when data from multiple cohorts of adult mice were combined, body fat was 47 and 45% lower in Dagla and Cnr1 KO mice, respectively, relative to WT values. By contrast, neither Daglb nor Napepld KO mice were lean. Weanling Dagla KO mice ate less than WT mice and had body weight (BW) similar to pair-fed WT mice, and adult Dagla KO mice had normal activity and VO2 levels, similar to Cnr1 KO mice. Our Dagla and Cnr1 KO mice also had low fasting insulin, triglyceride, and total cholesterol levels, and after glucose challenge had normal glucose but very low insulin levels. Dagla and Cnr1 KO mice also showed similar responses to a battery of behavioral tests. These data suggest: (1) the lean phenotype of young Dagla and Cnr1 KO mice is mainly due to hypophagia; (2) in pathways where ECs signal through Cnr1 to regulate food intake and other metabolic and behavioral phenotypes observed in Cnr1 KO mice, Dagla alone provides the 2-AG that serves as the EC signal; and (3) small molecule Dagla inhibitors with a pharmacokinetic profile similar to that of Cnr1 inverse agonists are likely to mirror the ability of these Cnr1 inverse agonists to lower BW and improve glycemic control in obese patients with type 2 diabetes, but may also induce undesirable neuropsychiatric side-effects.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | 2016
David R. Powell; Melinda Smith; Nathaniel L. Wilganowski; Angela L. Harris; Autumn Holland; Maricela Reyes; Laura Kirkham; Laura L. Kirkpatrick; Brian Zambrowicz; Gwenn M. Hansen; Kenneth A. Platt; Isaac Van Sligtenhorst; Zhi-Ming Ding; Urvi Desai
Delta-5 desaturase (D5D) and delta-6 desaturase (D6D), encoded by fatty acid desaturase 1 (FADS1) and FADS2 genes, respectively, are enzymes in the synthetic pathways for ω3, ω6, and ω9 polyunsaturated fatty acids (PUFAs). Although PUFAs appear to be involved in mammalian metabolic pathways, the physiologic effect of isolated D5D deficiency on these pathways is unclear. After generating >4,650 knockouts (KOs) of independent mouse genes and analyzing them in our high-throughput phenotypic screen, we found that Fads1 KO mice were among the leanest of 3,651 chow-fed KO lines analyzed for body composition and were among the most glucose tolerant of 2,489 high-fat-diet-fed KO lines analyzed by oral glucose tolerance test. In confirmatory studies, chow- or high-fat-diet-fed Fads1 KO mice were leaner than wild-type (WT) littermates; when data from multiple cohorts of adult mice were combined, body fat was 38% and 31% lower in Fads1 male and female KO mice, respectively. Fads1 KO mice also had lower glucose and insulin excursions during oral glucose tolerance tests along with lower fasting glucose, insulin, triglyceride, and total cholesterol levels. In additional studies using a vascular injury model, Fads1 KO mice had significantly decreased femoral artery intima/media ratios consistent with a decreased inflammatory response in their arterial wall. Based on this result, we bred Fads1 KO and WT mice onto an ApoE KO background and fed them a Western diet for 14 weeks; in this atherogenic environment, aortic trees of Fads1 KO mice had 40% less atheromatous plaque compared to WT littermates. Importantly, PUFA levels measured in brain and liver phospholipid fractions of Fads1 KO mice were consistent with decreased D5D activity and normal D6D activity. The beneficial metabolic phenotype demonstrated in Fads1 KO mice suggests that selective D5D inhibitors may be useful in the treatment of human obesity, diabetes, and atherosclerotic cardiovascular disease.
Archive | 2001
D. Wade Walke; Nathaniel L. Wilganowski; C. Alexander Turner
Archive | 2003
Gregory Donoho; Erin Hilbun; C. Alexander Turner; Glenn Friedrich; Alejandro Abuin; Brian Zambrowicz; Arthur T. Sands; D. Wade Walke; Nathaniel L. Wilganowski; Yi Hu; James Alvin Kieke; David Potter
Archive | 2001
D. Walke; Nathaniel L. Wilganowski; C. Turner
Archive | 2005
D. Walke; Nathaniel L. Wilganowski; C. Turner; Glenn Friedrich; Alejandro Abuin; Brian Zambrowicz; Arthur T. Sands
Archive | 2001
C. Alexander Turner; D. Wade Walke; Nathaniel L. Wilganowski
Archive | 2001
D. Wade Walke; Nathaniel L. Wilganowski; Carl Johan Friddle
Archive | 2001
Gregory Donoho; C. Alexander Turner; D. Wade Walke; Nathaniel L. Wilganowski
Archive | 2001
D. Wade Walke; Nathaniel L. Wilganowski; C. Alexander Turner; Glenn Friedrich; Alejandro Abuin; Brian Zambrowicz; Arthur T. Sands